634 related articles for article (PubMed ID: 26297356)
1. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
2. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
3. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
Nielsen T; Wallden B; Schaper C; Ferree S; Liu S; Gao D; Barry G; Dowidar N; Maysuria M; Storhoff J
BMC Cancer; 2014 Mar; 14():177. PubMed ID: 24625003
[TBL] [Abstract][Full Text] [Related]
6. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
7. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
8. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
9. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
10. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
[TBL] [Abstract][Full Text] [Related]
11. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Chia SK; Bramwell VH; Tu D; Shepherd LE; Jiang S; Vickery T; Mardis E; Leung S; Ung K; Pritchard KI; Parker JS; Bernard PS; Perou CM; Ellis MJ; Nielsen TO
Clin Cancer Res; 2012 Aug; 18(16):4465-72. PubMed ID: 22711706
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
[TBL] [Abstract][Full Text] [Related]
13. Translating Research into Practice: the Prosigna® (PAM50) Gene Signature Assay.
Boccia RV
Clin Adv Hematol Oncol; 2015 Jun; 13(6 Suppl 6):3-13. PubMed ID: 26191941
[TBL] [Abstract][Full Text] [Related]
14. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Rasmussen BB; Knoop AS; Buckingham W; Ferree S; Schaper C; Nielsen TO; Haffner T; Kibøl T; Møller Talman ML; Bak Jylling AM; Tabor TP; Ejlertsen B
J Clin Oncol; 2018 Mar; 36(8):735-740. PubMed ID: 29369732
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A; Galván P; Jimenez B; Buckingham W; Jeiranian HA; Schaper C; Vidal M; Álvarez M; Díaz S; Ellis C; Nuciforo P; Ferree S; Ribelles N; Adamo B; Ramón Y Cajal S; Peg V; Alba E
Clin Cancer Res; 2016 Feb; 22(3):560-6. PubMed ID: 26152740
[TBL] [Abstract][Full Text] [Related]
16. Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer.
Lien TG; Ohnstad HO; Lingjærde OC; Vallon-Christersson J; Aaserud M; Sveli MAT; Borg Å; Osbreac OBO; Garred Ø; Borgen E; Naume B; Russnes H; Sørlie T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885228
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
18. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA; Hanna H; Nassar A
Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
[TBL] [Abstract][Full Text] [Related]
19. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
20. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
